.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
McKesson
AstraZeneca
Novartis
Fish and Richardson
US Army
Colorcon
Moodys
Chubb
Citi

Generated: December 13, 2017

DrugPatentWatch Database Preview

Claims for Patent: 7,608,616

« Back to Dashboard

Claims for Patent: 7,608,616

Title:Methods for reducing the risk of an adverse drug interaction in a patient suffering from insomnia
Abstract:Disclosed herein is a method for treating a patient with Quazepam that reduces the risk of an adverse interaction between the Quazepam and drug that is a substrate of the cytochrome P450 enzyme isoform 2B6 (CYP2B6 substrate drug), e.g., Bupropion. The method includes determining if the patient to be treated with Quazepam is being treated with a CYP2B6 substrate drug, and prescribing or treating the patient with Quazepam based on the determination.
Inventor(s): Cartt; Steve (Union City, CA)
Assignee: Questcor Pharmaceuticals, Inc. (Union City, CA)
Application Number:12/132,575
Patent Claims: 1. A method for reducing the risk of an adverse drug interaction in a patient suffering from depression, comprising (i) determining if the patient is also suffering from insomnia and is being treated with bupropion, and (ii) prescribing or administering to the patient a therapeutically effective amount of quazepam to treat the insomnia if and only if the patient is not being treated with bupropion.

2. The method of claim 1, wherein the patient is not being treated with bupropion, further comprising prescribing or administering to the patient an antidepressant drug other than bupropion.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Covington
Chubb
Julphar
Federal Trade Commission
Johnson and Johnson
Accenture
AstraZeneca
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot